Novel T-Cell Immunotherapy Market

Novel T-Cell Immunotherapy Market Overview

The novel T-cell immunotherapy market is estimated to be worth $25 million in 2021 and is expected to grow at CAGR of 76% during the forecast period. In recent years, adoptive T-cell therapy (ACT) has emerged as a potent and viable type of therapeutic intervention, which is applicable to a variety of oncological and non-oncological indications. Owing to its obvious benefits, which include high target specificity, customization potential and the ability to generate immunological memory, this form of therapy has garnered significant attention among drug developers, investors and consumers, alike. In fact, several of the initial variants of T-cell based pharmacological interventions, namely those based on chimeric antigen receptors (CARs), and antigen sensitized T-cell receptors (TCRs), are already approved and available in the market.

Lately, several novel types of T-cell therapies, such as γδ T-cells, Tregs, activated T-cells, virus-driven T-cells and T-cell vaccines, have demonstrated therapeutic proof-of-concept and shown promise in the early stages of clinical research, as well. Much like their predecessors, these experimental treatment paradigms are also capable of selectively eradicating diseased cells from the body and are characterized by favorable side effect profiles. At present, the novel T-cell immunotherapies pipeline features over 200 product candidates and is anticipated to grow in the foreseen future. Further, more than 35 such therapies, including Tab-cel® (Atara Biotherapeutics), CLBS03 (Caladrius Biosciences), TVI-Brain-1 (TVAX Biomedical), Viralym-M (AlloVir) and ALS001 (Coya Therapeutics), are already being evaluated in the advanced stages of development.

So far, more than 105 academic / research institutes, as well as over 50 industry players, across the world, have made notable contributions to this upcoming segment of the T-cell therapy market. Moreover, multiple collaborations have been inked between both industry and non-industry players in order to advance the development of various pipeline candidates, over the past decade alone. It is also worth highlighting that, in the last five years, capital investments worth over USD 4 billion were made by VC firms / other strategic investors with interest in the healthcare domain. Driven by promising clinical trial data and lucrative funding, this niche, but emerging market, is poised to witness healthy market growth during the forecast period.

Key Companies in Novel T-Cell Immunotherapy Market

Examples of key companies engaged in novel T-cell immunotherapy market (which have also been profiled in this market report; the complete list of CAR T cell therapy companies is available in the full report) include Atara Biotherapeutics, AlloVir, Eureka Therapeutics, Eutilex, GammaDelta Therapeutics, NexImmune, OSE Immunotherapeutics, Tevogen Bio and WindMIL Therapeutics. This market report includes an easily searchable excel database of all the companies developing novel T-cell therapy, worldwide.

Recent Developments in Novel T-Cell Immunotherapy Market

Several recent developments have taken place in the field of novel T-cell immunotherapy market. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.

• In August 2026, A first-in-human clinical trial evaluated a novel off-the-shelf T-cell immunotherapy combining engineered T-cell receptors with natural killer cells targeting MAGE-A4.
• In July 2026, Peter MacCallum Cancer Centre secured a $17.7 million grant from Australia’s Medical Research Future Fund to advance a next-generation CAR-T cell immunotherapy into human trials.
• In May 2026, The University of Texas MD Anderson Cancer Center received FDA clearance for an Investigational New Drug application for a novel CAR-T cell therapy targeting CD94+ relapsed or refractory T/NK cell lymphomas.
• In April 2026, Roswell Park Comprehensive Cancer Center launched a Phase 1 clinical trial of a novel CD83-targeting CAR-T cell therapy for relapsed or refractory acute myeloid leukemia.

Scope of the Novel T-Cell Immunotherapy Report

The “Novel T-Cell Immunotherapy Market: Focus on γδ T-Cells, Tregs,  Activated T-Cells, Virus-driven T-Cells and T-Cell Vaccines - Distribution by Type of T-cell Therapy (Activated T-cell, T-cell Vaccine, Treg and Virus-driven T-cell), Target Indications (Brain Tumor, Pancreatic Cancer, Breast Cancer, Lung Cancer, Nasopharyngeal Cancer, Multiple Myeloma, Hepatocellular Carcinoma, Post-transplant Infection, Diabetes and Others), Key Players and Key Geographies (North America, Europe, Asia Pacific and Rest of the World), Industry Trends and Global Forecast, 2021-2030” market report features an extensive study of the current market landscape, market size, market share, market forecast, market outlook and future opportunities for T-cell therapy market. The market research report highlights efforts of both industry players and academic organizations.

Amongst other elements, the market research report features the following:

• A detailed assessment of the current market landscape of novel T-cell immunotherapies, with respect to type of T-cell therapy (activated T-cells, virus driven T-cells, Tregs, γδ T-cells, T-cell vaccines and NK T-cells), phase of development (preclinical, phase I, phase I/II, phase II, phase III and marketed), therapeutic area (oncological disorders, infectious diseases, post-transplant infections, autoimmune disorders, metabolic disorders and neurological disorders), popular target indication (lung cancer, breast cancer, cytomegalovirus infection, glioblastoma, hepatocellular carcinoma, acute myeloid leukemia, ovarian cancer, type 1 diabetes mellitus, sarcoma, HIV infections and pancreatic cancer), source of T-cell (autologous and allogeneic), route of administration (intravenous, intratumoral, subcutaneous, inhalation and intramuscular), dose frequency (multiple dose, single dose and split dose), target patient segment (children, adults and seniors), type of therapy (monotherapy and combination therapy) and type of developer (industry and non-industry). In addition, the chapter includes details related to novel T-cell immunotherapies developers, along with information on their respective year of establishment, company size, location of headquarters and most active players (in terms of number of pipeline candidates).
• An in-depth analysis of completed, ongoing and planned clinical studies of various novel T-cell immunotherapies, based on various relevant parameters, such as trial registration year, trial phase, trial recruitment status, study design, type of sponsor / collaborator, leading industry players (in terms of number of registered trials conducted), enrolled patient population and key geographical regions.
• An analysis of the partnerships that have been established in T-cell therapy market during the period 2015-2021 (till March), covering R&D agreements, product development agreements, product licensing agreements, acquisitions, service agreements, manufacturing agreements and other related agreements.
• An analysis of investments that have been made into CAR T cell therapy companies which have proprietary novel T-cell based products / technologies, during period 2014 and 2021 (till March). The various type of funding instances reported in T-cell therapy market include seed financing, venture capital financing, capital raised from IPOs and subsequent public offerings, grants and debt financing.
• Detailed profiles of clinical stage, novel T-cell therapies (phase I/II or above); each profile features an overview of the therapy, current development status, key clinical trial results, dosage regimen, details related to its manufacturing and recent developments.
• A case study on manufacturing of cell therapy products, highlighting the key challenges associated with the production of such therapies. In addition, it features a detailed list of contract service providers and in-house manufacturers involved in this market.
• Elaborate profiles of prominent players engaged in the development of novel T-cell immunotherapies. Each profile features a brief overview of the company, details related to its financials (if available), product portfolio, recent developments and manufacturing capability. 
• A case study on regulatory T-cells, highlighting the mechanism of Tregs, key challenges associated with the production of such therapies and recent developments in the Tregs market.

The key objective of novel T-cell immunotherapy market report is to provide a detailed market analysis in order to estimate the existing market size, market value, statistics and future opportunity for novel T-cell immunotherapy market during the forecast period. The market research report also includes likely sales forecasts of novel T-cell immunotherapies that are in the mid to late stages of development. Additionally, it features market size projections for the overall novel T-cell immunotherapy market, wherein both the current and upcoming opportunity is segmented across [A] type of T-cell therapy (activated T-cell, T-cell vaccine, Treg and virus-driven T-cell), [B] target indication (brain tumour, pancreatic cancer, breast cancer, lung cancer, nasopharyngeal cancer, multiple myeloma, hepatocellular carcinoma, post-transplant infection, diabetes and others), [C] key players and [D] key geographies (North America, Europe, Asia Pacific and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely the conservative, base and optimistic scenarios, which represent different tracks of the industry’s evolution.

The opinions and insights presented in this market report were influenced by discussions conducted with multiple stakeholders in T-cell therapy market. The market research report features detailed transcripts of interviews held with the following individuals:

• Chief Executive Officer, Small Company, US
• Senior Vice President of Strategy, Planning and Operations, Small Company, US